TITLE

Halaven

PUB. DATE
December 2010
SOURCE
Pharmaceutical Representative;Dec2010, Vol. 40 Issue 12, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the U.S. Food and Drug Administration's (FDA) approval of Halaven from Eisai for treating patients with metastatic breast cancer.
ACCESSION #
56527569

 

Related Articles

  • ODAC supports neoadjuvant Perjeta regimen for HER-2-positive breast cancer.  // Hem/Onc Today;10/10/2013, Vol. 14 Issue 19, p31 

    The article reports that a U.S. Food and Drug Administration (FDA) panel unanimously supported the approval of pertuzumab as part of a neoadjuvant treatment regimen for patients with HER-2-positive breast cancer.

  • Pfizer Seeks Early Approval Of Breast Cancer Drug. AMY REEVES // Investors Business Daily;5/16/2014, p00 

    The article reports on the plan of pharmaceutical company Pfizer Inc. to file for U.S. approval of its breast-cancer drug palbociclib before it finishes clinical trials.

  • New Treatment for Advanced Breast Cancer.  // Clarendon Enterprise (TX);11/1/2007, Vol. 18 Issue 46, p7 

    The article reports that the Food and Drug Administration (FDA) has approved the Ixempera, a new treatment for advanced breast cancer in the U.S.

  • Targeted therapies continue to improve outcomes in HER-2--positive breast cancer. Southall, Jennifer R. // Hem/Onc Today;6/10/2013, Vol. 14 Issue 11, p1 

    The article focuses on the move of the U.S. Food and Drug Administration (FDA) to approve ado-trastuzumab emtansine for HER-2-positive breast cancer treatment, which will fourth drug approved by the regulatory board for use against the said disease.

  • Approving pre-surgery cancer drugs.  // Nature Reviews Drug Discovery;Nov2013, Vol. 12 Issue 11, p817 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the pertuzumab, a neoadjuvant breast cancer drug, from medical companies Roche and Genentech.

  • LEGAL/REGULATORY.  // Medical Marketing & Media;Feb2016, Vol. 51 Issue 2, p9 

    The article focuses on several drugs approved by the U.S. Food & Drug Administration (FDA) in 2015 including the Pfizer's Ibrance, breast-cancer treatment, Boehringer Ingelheim's Praxbind, drug that changes the blood-thinning effects of the anticoagulants, and the Okambi, cystic fibrosis treatment.

  • Ixabepilone Treatment Schedules in Advanced Breast Cancer. Egerton, Nancy // European Journal of Clinical & Medical Oncology;2012, Vol. 4 Issue 1, p49 

    Ixabepilone, the first of a new class of microtubule-stabilizing anticancer agents, is approved in 17 countries worldwide. It was approved by the Food and Drug Administration in 2007 for treatment of patients with locally advanced or metastatic breast cancer progressing after taxanes and...

  • Are Thiazolidinediones (TZDs) Safe?  // Clinical Oncology Alert;Nov2007, Vol. 23 Issue 11, p1 

    This section offers news briefs on issues related to pharmacology. These include a discussion on the safety of thiazolidinediones (TZDs), rosiglitazone (Avandia), and pioglitazone (Actos). It says that a single 5 milligram infusion of zoledronic (Zometa) within 90 days of a hip fracture lessened...

  • Genentech Caught off Guard, FDA Issues Refuse-to-File for T-DM1. Hollingsworth, Catherine // BioWorld Today;8/30/2010, Vol. 21 Issue 167, p1 

    The article focuses on a refuse-to-file letter sent by the U.S. Food and Drug Administration (FDA) to Genentech Inc. rejecting its application for an accelerated approval of its trastuzumab-DNA methyltransferase inhibitor (T-DMI). Genentech conducted a study which indicated that T-DMI reduced...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics